This finding was corroborated by repeated analyses using an alternative LDL-C dataset (OR = 0.412, 95%CI: 0.035–0.859, p = 1.05 × 10−4, Table 1), reinforcing the conclusion that PCSK9 inhibitors demonstrate a substantial effect in reducing CHD risk. This evidence concerns the gene PCSK9 and coronary artery disorder.